Drug Search Results
More Filters [+]

Ritobegron

Alternative Names: ritobegron, kuc-7483, kuc7483, kuc 7483
Latest Update: 2023-09-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADRB3 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ritobegron

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Overactive Bladder

Phase 1: Healthy Volunteers|Spinal Cord Injuries

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02256735

P1

Completed

Healthy Volunteers

2005-12-01

NCT02256722

P1

Completed

Healthy Volunteers

2005-11-01

2004-004590-28

P2

Completed

Overactive Bladder

2005-06-30

NCT02259751

P1

Completed

Spinal Cord Injuries

2005-02-01

Recent News Events